-
Antengene Submits New Drug Application for Selinexor in Taiwan, China for the Treatment of Three Indications in Hematologic Malignancies
prnasia
July 14, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
-
Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
prnasia
January 25, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced today that the ...
-
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
prnasia
January 04, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that it has submitted ...
-
Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
prnasia
December 07, 2020
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the ...